Immunovant (IMVT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.68
- Estimate
- -$0.61
- Surprise
- -10.5%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Immunovant (IMVT) reported a wider loss than forecast — diluted EPS of -$0.68 against the -$0.61 estimate (a 10.5% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates IMVT Sell at 4.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -10.5% surprise compares with a +3.7% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: IMVT-1402
- Concentration risk — Supplier: Ypsomed AG
- Quality below floor (1.3 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $36.38
- Price target
- $43.99
- Stop
- $35.03
- Upside to target
- +20.9%
- Reward-to-risk
- 2.5:1
Risk check: RSI 8 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
IMVT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $7.57B
- P/E (fwd)
- -13.3
- 52-week range
- $14.58–$45.42
- Off 52-week high
- 19.9%
- RSI (14)
- 8
- Volume vs avg
- 1.00×
- Score today
- 4.8/10